glp-1 drugs review The New GLP-1 Agonists Explained: Definition, How

Diarrhea: Gastrointestinal disturbances, including diarrhea, can occur with GLP-1 therapy

Contrastingly, GLP1 antagonist sales in 2023 showcase a more diversified landscape, with therapeutics such as Ozempic, Trulicity, and Mounjaro driving 71 per cent of the sales. Looking ahead, the GLP1 agonist market is poised for robust growth, anticipating a 19.2 per cent compound annual growth rate (CAGR) from 2023 to 2029, reaching a substantial market size of $105 billion in 2029

This causes insulin release, slows gastric emptying, and suppresses secretion of glucagon (a hormone that increases blood sugar)

Pharmacological management of polycystic ovary syndrome

Although GLP-1RAs can attenuate inflammatory tone [105], sustained reductions in nutrient inflow associated with pharmacological weight loss may influence NAD turnover kinetics in metabolically stressed tissues

Current Opinion in Rheumatology